Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Insider Trading Scheme Concludes With Guilty Plea

This article was originally published in The Pink Sheet Daily

Executive Summary

The first-ever prosecution of an agency employee will likely result in jail time for the chemist. For the agency, the result is a new electronic monitoring system.

You may also be interested in...



FDA's Confidential Information Protections Draw Questions From Congress

House Energy & Commerce Committee leaders ask what additional steps agency has taken to safeguard trade secrets in wake of insider trading charges against former FDA official.

Insider Trading: Pharma Employees Increasingly In SEC Crosshairs

In past month, three individuals in biopharma space have been charged with insider trading despite efforts by companies and associations to protect confidential information; past sentencing suggests length of jail time former FDA official Gordon Johnston is likely to face.

FDA Seeks New Chief Information Officer In Privacy And Security Overhaul

The CIO will help develop policy to protect sensitive information while balancing individual privacy and security. FDA restructured the organization with a chief health informatics officer – focused on research, development, scientific computing and big data – and the CIO for software development and deployment, infrastructure and customer service.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS072902

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel